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Incidence of atrial fibrillation in different
major cancer subtypes: a Nationwide
population-based 12 year follow up study
Christina Boegh Jakobsen1* , Morten Lamberts1, Nicholas Carlson1,2, Morten Lock-Hansen1,
Christian Torp-Pedersen3, Gunnar H. Gislason1 and Morten Schou1
Abstract
Background: The prevalence of both atrial fibrillation (AF) and malignancies are increasing in the elderly, but
incidences of new onset AF in different cancer subtypes are not well described.The objectives of this study were
therefore to determine the incidence of AF in different cancer subtypes and to examine the association of cancer
and future AF.
Methods: Using national databases, the Danish general population was followed from 2000 until 2012. Every
individual aged > 18 years and with no history of cancer or AF prior to study start was included. Incidence rates of
new onset AF were identified and incidence rate ratios (IRRs) of AF in cancer patients were calculated in an
adjusted Poisson regression model.
Results: A total of 4,324,545 individuals were included in the study. Cancer was diagnosed in 316,040 patients. The
median age of the cancer population was 67.0 year and 51.5% were females. Incidences of AF were increased in all
subtypes of cancer. For overall cancer, the incidence was 17.4 per 1000 person years (PY) vs 3.7 per 1000 PY in the
general population and the difference increased with age. The covariate adjusted IRR for AF in overall cancer was
1.46 (95% confidence interval (CI) 1.44–1.48). The strength of the association declined with time from cancer
diagnosis (IRR0-90days = 3.41 (3.29–3.54), (IRR-180 days-1 year = 1.57 (CI 1.50–1.64) and (IRR2–5 years = 1.12 (CI 1.09–1.15).
Conclusions: In this nationwide cohort study we observed that all major cancer subtypes were associated with an
increased incidence of AF. Further, cancer and AF might be independently associated.
Keywords: Atrial fibrillation, Arrhythmia, Cancer, Malignancy
Background
Atrial fibrillation (AF), repeatedly named the new epi-
demic in cardiology [1, 2], affects 1.5–2% of the general
population and prevalence is likely to double within the
next 50 years [3]. AF is a major risk factor for developing
cardiovascular complications, and is associated with a 5-
fold increased risk of stroke, a 3-fold incidence of heart
failure and an increased mortality [3]. Besides age,
several cardiovascular conditions such as hypertension,
valvular heart disease and heart failure, as well as non-
cardiovascular conditions such as diabetes, chronic
pulmonary disease, obesity, surgery and alcohol are
established risk factors for AF [3–6]. Cancer is associ-
ated with an increased inflammatory activity [7–9] and
paraneoplastic manifestations [10, 11]. However, it is un-
known whether cancer is an independent risk factor for
development of AF [12].
Knowledge regarding the association of cancer and AF
is very sparse and it has only been examined in a few
studies. One case-control study [13] observed an in-
creased risk of AF in all cancer subtypes when compared
to non-cancer patients, but only within the first 90 days
after the cancer diagnosis. Another observational cohort
study among women found similar results, with in-
creased risk of AF the first 3 months following a cancer
diagnosis [14]. Finally a small cohort study [15] has
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described an increased association between breast cancer
or colorectal cancer and future AF. Whether the in-
creased risk of AF is associated with all subtypes of can-
cer or only limited to certain subtypes is unknown at
present. Furthermore, the incidence, clinical significance
and appearance of new onset of AF in relation to the
time of the cancer diagnosis are also unknown [12].
The objectives of this study are, therefore, to describe
the incidence of AF and its appearance in relation to
time from diagnosis of cancer in different cancer sub-
types, and to test whether cancer is an independent risk
factor for AF or whether it is explained by comorbidity
associated with cancer.
Methods
Registries
In Denmark every citizen has a unique personal regis-
tration number. We used this number to link individ-
ual data across several nationwide databases: The
National Patient Registry classifies all hospital con-
tacts with regards to the International Classification
of disease (ICD). Procedures performed are coded ac-
cording to the Nordic Medical Statistics committee of
Surgical Procedures. The National Prescriptions regis-
try provides information regarding the dose, number
of tablets and the date of dispensing according to the
Anatomical Therapeutic Chemical Classification sys-
tem. Vital status, gender, and cause of death accord-
ing to the ICD 10th revision were acquired from the
Danish Personal Registration System and the National
Causes of Death Register. Diagnosis, pharmacother-
apy, surgical procedures and comorbidities used to
identify and define the population are available in
Additional file 4.
Study population
All Danish citizens aged 18 years of age or above were
included January 1, 2000. Individuals diagnosed with AF
or cancer prior to inclusion were excluded, hence at in-
clusion all individuals were categorized as the general
population (i.e. not having cancer). If diagnosed with
cancer during follow-up, subjects changed status from
general population to the cancer group at the date of
their cancer diagnosis. Thus in the statistical analyses,
patients who developed cancer during the study, did not
appear as a part of the endpoint results in the general
population. The cohort was followed until either the de-
but of AF, emigration, death, or December 31st 2012,
whichever came first. Figure 1 depicts the study popula-
tion. Patients diagnosed with cancer were sub grouped
according to type of cancer. For patients registered with
more than one type of cancer, only the first cancer diag-
nosis was included in the study.
Comorbidity and pharmacotherapy
The prevalence of the following comorbidities were
characterized at inclusion: Ischemic stroke, myocardial
infarction, previous embolus, liver disease, abuse of alco-
hol or psychoactive substances, previous bleeding, vascu-
lar disease, chronic renal failure, chronic obstructive
pulmonary disease, thyroid disease, heart failure, and
hypertension. Heart failure was defined as a prior diag-
nosis of heart failure plus the use of loop diuretic as
done previously [16, 17]. Hypertension was defined as a
combination treatment with a least two antihypertensive
drugs as done previously [16, 18, 19] .
Pharmacotherapy was characterized for the following
drugs; loop diuretics, renin-angiotensin system inhibi-
tors, beta-blockers, aldosterone antagonists, thiazides,
statins, anti-platelet therapies, vitamin K antagonists,
anti-diabetes medication, and inhalation therapies for
obstructive pulmonary diseases.
We report comorbidities and pharmacotherapy at the
time of inclusion, and also at the time of the cancer
diagnosis. Prescriptions redeemed within 180 days prior
to inclusion and cancer diagnosis defined treatment.
Study outcomes
AF was identified by the ICD-10 diagnosis code ‘DI48’
from The National Patients Registry. The diagnostic
coding for AF has previously been validated; where the
positive predictive value was 93%, and results were
comparable between AF primary and or secondary diag-
noses [20]. In our main analyses, any primary or second-
ary diagnosis of AF was included in order to capture all
hospitalizations related to AF. However, this captures
random findings of non-symptomatic AF in relation to
acute conditions being the primary reason for
hospitalization. To ensure that our results were not
biased, we furthermore conducted a sensitivity analysis,
where we solely included cases of AF registered as the
primary diagnosis.
Statistical analysis
All presented rates are crude incidence rates (IR) calcu-
lated as events per 1000 person-years (PY) with 95%
confidence intervals (CIs). Additionally, the incidence
rates were stratified by sex and presented with continu-
ously updated patient age (and age group accordingly).
The lexis-macro (http://www.bendixcarstensen.com/
Lexis/Lexis.sas last accessed January 21, 2016) was used
for all analyses and included three time scales; calendar
time (bands were split in 1 year periods after 1th January
2000), age (bands were split in 1 year periods according
to date of birth) and time from cancer diagnosis (bands
were split after 3, 6, 12, 24, 60 and > 60 months respect-
ively from date of cancer diagnosis).
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Multivariable Poisson regression models were fitted to
estimate incidence rate ratios (IRRs) of AF in cancer pa-
tients with the general population as reference. We de-
fined two models. (I) An analysis only adjusted for age
and gender, and (II) a fully adjusted time dependent ana-
lysis (i.e. continuously assessment and update of charac-
teristics during the entire study period)) adjusted for
age, gender, calendar time, and including adjustment for
the above mentioned comorbidities (ischemic stroke,
myocardial infarction, previous embolus, liver disease,
abuse of alcohol or psychoactive substances, previous
bleeding, vascular disease, chronic renal failure, chronic
obstructive pulmonary disease, thyroid disease, heart
failure, and hypertension) and pharmacotherapy (loop
diuretics, renin-angiotensin system inhibitors, beta-
blockers, aldosterone antagonists, thiazides, statins, anti-
platelet therapies, vitamin K antagonists, anti-diabetes
medication, and inhalation therapies for obstructive pul-
monary diseases). As AF is known to be seen
postoperatively, [6], the regression model were further
adjusted for all major gastric-, orthopedic-, thoracic and
cardiac surgeries, including cancer-related surgeries, per-
formed within 30 days prior to an AF diagnosis. Only
surgeries requiring hospitalization for 3 days or more
were included, (assuming severe disease or surgery more
prone to AF development). The adjustments for major
surgeries were used for both the cancer population and
the non-cancer population. In the fully adjusted model,
each patient following inclusion was split into multiple
observations according to the criteria above. i.e. three
time scales, date of dispensed new prescription or co-
morbidity and surgery. All patients were followed from
inclusion until a diagnosis of AF, death, emigration and
study end, whichever came first.
To ensure a potential association between AF and
cancer was not solely influenced by AF being diagnosed
at time of a cancer diagnosis, we defined a third model,
where we performed analyses within time periods from
Fig. 1 The study population. Flowchart of the study population
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cancer diagnosis i.e. “0–90 days”, “90–180 days”, “180–
365 days”, “1–2 years”, “2–5 years”, and “> 5 years”.
A two tailed P-value ≤0.05 was considered significant.
We tested for relevant interaction and no clinical rele-
vant violation of model assumptions were found (linear-
ity, goodness-of-fit). Data management and statistical
analyses were performed using SAS version 9.4.
Ethics
The study has been approved by the Danish Data
Protection Agency (2007-58-0015 / local ref. no. GEH-
2014-013, I-Suite no: 02731. Data was made available to
us, so no individuals could be identified. As a retrospect-
ive registry-based study, Danish law does not require
ethical approval.
Results
Study population
A total of 4,324,545 people from the general Danish
population were included on January 1st, 2000. During
12 years of follow-up, 316,040 persons (7.3%) were diag-
nosed with cancer with a female predominance of 51.5%
and a median age at disease onset of 67.0 years (IQR
58.0–75.8). Figure 1 shows a flow chart of the study
population and Table 1 shows clinical characteristics of
the patients who developed cancer and of the general
population.
Incidence of AF after a cancer diagnosis: sex and cancer
type stratified analyses
The crude incidence rates of AF in cancer patients
stratified according to time from cancer diagnosis until
AF diagnosis are shown in Fig. 2. Figure 3 shows the
crude incidence rates according to cancer and sex. The
incidence rate is highest for AF diagnosed within 90 days
from the date of the cancer diagnosis, but remains
higher than the incidence rate for the general population
without cancer for more than 5 years. For every cancer
type, the incidence rates of AF is greater compared with
the incidence rate of the general population. In the gen-
eral population the incidence of AF was 3.7 per 1000
person years (PY) compared to 17.4 per 1000 PY in pa-
tients with a cancer diagnosis (excluding the first 90 days
the rate was 13.7 per 1000 PY). The highest incidence
was observed in lung cancer in both men (58.7 per 1000
PY) and women (35.3 per 1000 PY). Figures 4 and 5
show the gender-specific crude incidence rates of AF in
different major cancer types compared to the general
population. Both figures illustrate that the incidence of
AF in all subtypes of cancer increases as function of age
and follow up time for both women and men.
Association between cancer and incidence AF: Poisson
regression analyses
Age- and sex- adjusted and fully-adjusted (adding calen-
dar year, sex, age, former surgeries, comorbidities and
pharmacotherapy) incidence rate ratios (IRR) of AF are
shown for overall cancer in Figs. 6 and 7, respectively.
The figures illustrate that the association between overall
cancer and AF is highest within the first 90 days, but it
remains significant over time.
IRRs over time according to specific cancers largely re-
sembled main analysis. (Additional file 1: Table S1) Not-
ably, the IRRs for lung cancer and hematological cancer
Table 1 Baseline characteristics
Clinical characteristics General population
(n = 4,324,545)
Cancer
population
(n = 316,040)
Male sex 2,176,883 (50.3) 153,258 (48.5)
Median (SD*) age (years) 44.8 (18.0) 67.0 (13.3)
Comorbidity:
Stroke 63,619 (1.5) 19,589 (6.2)
Ischemic heart disease 64,596 (1.5) 17,297 (5.5)
Heart failure 22,271 (0.5) 6226 (2.0)
Hypertension 179,184 (4.1) 111,157 (35.2)
Vascular disease 83,119 (1.9) 25,590 (8.1)
Previous bleeding 27,104 (0.6) 36,996 (11.7)
Chronic obstructive pulmonary
disease
19,639 (0.5) 19,127 (6.1)
Chronic kidney disease 36,595 (0.9) 8962 (2.8)
Misuse of alcohol or psychoactive
substance
73,056 (1.7) 17,533 (5.6)
Hyperthyroid disease 29,945 (0.7) 9704 (3.1)
Previous embolus 81,350 (1.9) 26,708 (8.5)
Liver disease 27,104 (0.6) 9395 (3.0)
Pharmacotherapy
Calcium channel blocker 154,619 (3.6) 43,591 (13.8)
ACE† inhibitors 173,182 (4.0) 67,737 (21.4)
Beta blockers 158,308 (3.7) 42,629 (13.5)
Spironolactone 18,023 (0.4) 9132 (2.9)
Loop diuretic 118,914 (2.8) 35,159 (11.1)
Thiazide diuretic 168,222 (3.9) 43,289 (13.7)
Aspirin 175,178 (4.1) 60,598 (19.2)
Clopidogrel 1444 (0.03) 4488 (1.4)
Warfarin 1558 (0.5) 7376 (2.3)
Digoxin 41,430 (1.0) 6852 (2.2)
Cholesterol-lowering drug 62,599 (1. 5) 50,301 (15.9)
Glucose-lowering medication 8791 (2.9) 22,979 (7.2)
Inhalation medication 222,169 (5.1) 40,355 (12.8)
Baseline characteristics for the general population and the cancer population.
Values are numbers (percentages) unless stated otherwise
*SD = standard deviation, †ACE = angiotensin converting enzyme
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are markedly increased within the first 90 days and re-
main significantly increased 5 years after cancer
diagnosis.
Additional analyses: association between cancer and
future AF as primary diagnosis
We also conducted a sensitivity analysis, where only AF
as a primary diagnosis was used as an outcome, to
ensure that our results were not biased by
hospitalization for other reasons where AF was found by
chance. In these additional analyses, we found the IRR
for all cancer forms to be 1.23 (1.20–1.26) – compared
to 1.46 (1.44–1.48) when AF as a secondary diagnosis
was included. Contrary to the main analyses, the sub-
analysis only found a significantly increased IRR within
the first 5 years after the cancer diagnosis and thus not an
increased risk more than 5 years after (Additional file 2:
Table S2). For some cancers (i.e liver, pancreas or gall-
bladder, rectal, skin and urinary tract cancers), the associ-
ated risk of AF was comparable to the background
population 2 years following a diagnosis of cancer.
Discussion
Main findings of the present study are that in both men
and women, for all ages and major subtypes of cancer, a
cancer diagnosis is associated with an increased
incidence of new-onset AF. Second, cancer and future
AF seems to be independently associated. Finally and
importantly, AF appears more frequent in cancer pa-
tients up to 5 years following cancer diagnosis.
Other studies and mechanism(s)
Knowledge upon this topic is sparse. No previous studies
have investigated the incidence of AF in an unselected
cohort of patients with different forms of cancer. The as-
sociation between cancer and AF has only previously
been examined within subgroups of cancer or in connec-
tion with surgeries in smaller clinical studies. Thus there
are many open issues concerning the burden of AF in
cancer patients [12]. Our findings do, therefore, add
significant clinical data to the knowledge on the relation-
ship between cancer and new-onset AF. The mecha-
nism(s) underlying the association between cancer and
AF cannot be deduced based on our results and may
differ between the different cancer forms, e.g. the strong
correlation between lung cancer and AF suggests an
influence of direct tumor growth. It has also been
shown, that inflammatory markers such as C-reactive
protein are elevated in AF. As inflammation also plays a
large role in cancer, it is possible that cancer could lead
to AF through a systemic inflammatory state [7–9].
Finally the presence of paraneoplastic syndromes and
Fig. 2 Crude incidence rates of atrial fibrillation in cancer patients. The rates are stratified according to time from cancer diagnosis until
AF diagnosis
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neurohormonal activity could also lead to AF [10, 11].
The statistical association is, therefore, biological plaus-
ible and more research in the mechanism(s) are needed.
Incidence of AF
The incidence of AF stratified according to time and
subtypes of cancer is shown in Figs. 2 and 3. It may be
speculated that the observed difference is explained by
age, since cancer patients were older than the general
population (Table 1). We, therefore, performed age and
sex stratified analyses which confirmed that incidence of
AF was greatest in the cancer population (Figs. 4 and 5).
We observed a smaller difference in the incidence of AF
between cancer patients and the general population than
previously observed [15]. This may be explained by dif-
ferences in design, since we excluded known AF which
was not the case in the aforementioned study. Despite
the inherent limitations in our study, incidence rates
(both within the first 90 days and beyond) are markedly
increased and should raise concern from physicians
Fig. 3 Crude incidence rates of atrial fibrillation in the general population, in overall cancer patients and in individual types of cancer. The rates
are shown for the whole population and for women and men independently
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treating patients with malignancies. Rates of AF in pa-
tients with cancer are equivalent to rates found in pa-
tients with diabetes and rheumatoid arthritis [16, 21].
When looking at our entire study population, cancer
patients as well as non-cancer patients, we observed a
little lower incidence of AF than observed in other AF
studies [22, 23]. However, this can be explained by the
several factors; first of all by the differences in how AF is
defined. We defined AF by ICD10 codes, while the Fra-
mingham Heart Study [22] had access to e.g. Holter
monitoring and electrocardiograms for all of their par-
ticipants. Additionally the participants of the Framing-
ham Heart Study were between 50 and 89 years of age
and thus comparably older. As such, the observed inci-
dence of AF also reflects the correlation of age with risk
of AF. We observed the same incidence of AF in elderly
(> 80 years) general population as in the Rotterdam
Study (23).
The association between cancer and AF
Our findings support the current evidence [12] that an
association between cancer and future AF exists. The
correlation has up until now primarily been investigated
with regards to colorectal and breast cancer, but our re-
sults demonstrates that 12 out the 13 examined cancer
forms (including pulmonary cancer, prostate cancer,
urinary tract cancer and hematological cancer) were as-
sociated with increased risk of developing AF (Add-
itional file 3: Table S3). Additionally, the non-significant
association between endocrine cancer and future AF
could be due to under powering; hence incidence of
endocrine cancer was rare in our population (data not
shown).
Notably, two prior studies [13, 14] demonstrated that
the greater risk of AF in cancer patients was limited to
the initial 90 following cancer diagnosis; thus, indicating
that the association could be due to observations bias.
Fig. 4 Crude incidence rates of atrial fibrillation in females. Crude incidence rates of atrial fibrillation in the general female population and in
female patients with cancer. The model is stratified according to age and follow-up time
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This bias would emerge as asymptomatic cancer patients
have a greater chance of being diagnosed with AF than
asymptomatic otherwise healthy individuals. To
minimize the hazard of such bias we studied time from
date of cancer diagnosis until time of potential AF. Our
results show the same tendency; association between
cancer and AF is strongest within the first 90 days fol-
lowing the cancer diagnosis, thus also indicating the
presence of some degree of observation bias. However,
the association within our study remains significant as
long as 5 years following the cancer diagnosis. Therefore,
the presence of surveillance bias is unlikely to be the
solely explanation of our findings. The reason that we
find a significant association beyond 90 days could be
due to larger sample size (316,040 cancer patients).The
prognosis of cancer improves considerably these years
[24] and with a considerable burden of AF in the elderly
showed in our study among others, awareness of the de-
velopment of AF is important even in cancer patients
surviving a 5 year milestone.
As seen in Additional file 2: Table S2 and Add-
itional file 3: Table S3 the strongest association between
subtype of cancer and AF goes for lung cancer despite a
poor prognosis in these patients. On the other hand,
prostate cancer has the lowest significantly association
to AF despite a relatively good prognosis. It may, there-
fore, be argued that severity of the cancer disease or ana-
tomical location of the tumor is important factors for
development of AF. Also, time from the diagnosis of
cancer is an important factor to consider, especially con-
cerning cancer in the abdominal region.
Another possible explanation is the effect of specific
treatment for specific cancers, first line therapies for
prostate cancer includes local radiation, hormonal
Fig. 5 Crude incidence rates of atrial fibrillation in males. Crude incidence rates of atrial fibrillation in the general male population and in male
patients with cancer. The model is stratified according to age and follow-up time
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therapy and less invasive surgery (prostatectomy), which
all should be relatively less linked with development of
AF.
It is plausible, that the reason for the observed in-
crease in incidence of AF the first 90 days following can-
cer diagnosis could be related to the subclinical
progression of cancer prior to diagnosis. Patients pre-
senting with newly diagnosed cancer are predominantly
subject to the accumulated effects of prolonged disease
activity. As such, the debut of AF shortly after cancer
diagnosis could reflect the result of such prolonged
exposure.
Radiation and chemotherapy
Whether AF could emerge as a side effect to other sorts
of treatments of the cancer disease, such as radiation
therapy or chemotherapy have not been investigated in
this study. Especially with regards to lung cancer and
breast cancer it is possible that radiation therapy could
be involved in causing AF due to direct radiation against
the heart. However, looking at the individual IRR of the
cancer types, the association is actually higher for cancer
in the digestive system and cancer in the central nervous
system than for breast cancer suggesting that the
association in some cancer types must be explained by
other factors than radiation therapy.
Furthermore, due to the fact that chemotherapy is
considered in-hospital treatment in Denmark, our regis-
tries do unfortunately not contain exact data with
regards to type of chemotherapy or the duration of treat-
ment. Although AF incidence was especially pronounced
within the first 90 days, which could be the possible ef-
fect of certain types of chemotherapies, the association
of AF risk and cancer was still elevated beyond 90 days.
The scope of this study was to assess the association
(and not the causal path way) between different types of
cancers AF on a population level. Studies on the impact
of specific chemotherapies on AF risk are needed as no
information on chemotherapies was available for the
current study. This important limitation should be rec-
ognized when interpreting our findings.
Strengths and limitations
The strengths of this study include the inclusion of the
complete Danish population independent of age, gender,
ethnicity and participation in health insurance programs.
Due to these aspects the risk of information and referral
bias is reduced. Still, some limitations should be consid-
ered when interpreting the results.
Fig. 6 Incidence rate ratios of atrial fibrillation. Risk of atrial fibrillation among patients with cancer compared to persons without cancer -
stratified according to time from cancer diagnosis until AF diagnosis. The model is adjusted for sex and age
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The largest limitation in the present study is the de-
pendence on registry data. The identification of our
study end point, AF, relied on the presence of an AF dis-
charge code, but not by a validated electrocardiogram.
However, the positive predictive value of the diagnosis
of atrial fibrillation and flutter has been reported to be
93% [20] and the accuracy of other hospital registry
diagnoses are similar high [25].
In general, post-operative AF is one of the most com-
mon complications to surgeries, cardiac as well as none
cardiac surgeries. However, we have sought to eliminate
this potential confounding by adjusting for all major sur-
geries The association is, therefore, not likely to be
driven only by former surgeries.
Since the symptoms of AF are perceived in very indi-
vidual ways, and sometimes not at all, it is very likely
that some people were suffering from subclinical AF,
which may have resulted in misclassification of AF. It
may be speculated that cancer patients are more aware
of symptoms, and subclinical AF, therefore, is more fre-
quent in the general population, who ignore symptoms.
This may have biased our results in favor of an associ-
ation between cancer and AF towards one. Further, due
to more regular medical examinations in patients with
cancer, the risk of surveillance bias will emerge in
relation to subclinical AF in the no AF group of cancer
patients. When the analyses were limited to cases where
AF was the primary cause to hospitalization and thus
trying to eliminate AF cases randomly diagnosed in rela-
tion to cancer control, the association was less strong,
possibly due to a smaller number of outcomes. However,
tendency of the results were overall the same. Our re-
sults are, therefore, not solely the effect of surveillance
bias and misclassification.
As seen in Table 1 the groups differ from each other
with respect to clinical characteristics; however the mul-
tivariable regression analyses have been adjusted for
these differences in characteristics.
Furthermore, our registries do not provide information
regarding AF diagnoses solely treated by general practi-
tioners. Patients with uncomplicated and subclinical AF
who never have been hospitalized in relation to AF will
therefore not be included in our study. This could po-
tentially lead to an underestimation of the incidence of
AF in both groups.
Thus, residual confounding cannot be excluded since
clinical parameters such as blood pressure and HBA1C
were not measured. We were unable to adjust for poten-
tial clinical confounders such as obesity and smoking
and as some cancer forms are associated with a higher
Fig. 7 Incidence rate ratios of atrial fibrillation. Risk of atrial fibrillation among patients with cancer compared to person without cancer stratified
according to time from cancer diagnosis until AF diagnosis. The model is adjusted for time, age, sex, comorbidities and earlier surgeries
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prevalence of smoking or obesity, availability of such in-
formation could have changed the risk estimates. We did
not echocardiographic data on valve disease. Some of this
unmeasured confounding was probably accounted for in
the analyses by adjustment for lifestyle associated diseases.
It is, therefore, unlikely that our results only originate
from lack of data on other potential confounders.
Conclusions
Among more than 300,000 individuals diagnosed with
cancer, the incidence and risk of new-onset AF was sig-
nificantly increased compared to the general population.
Especially lung and gastrointestinal cancers were associ-
ated with considerable high rates. The association was
observed for 12 out of 13 cancer types and the estimates
decreased over time. Further, cancer and AF might be
independently associated. Future studies need to focus
on prognosis, risk of thromboembolic complications and
treatment, but also on risk factors, pathogenic mecha-
nisms and the impact of different treatment regimes for
development of AF in cancer patients.
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